AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19530147 — intervention group
Group type: EXPERIMENTAL
Intervention: XIENCE V stent
Number of subjects: 1002
Study 19530147 — intervention group
Group type: COMPARATOR
Intervention: TAXUS stent
Number of subjects: 1002
Study 16372689 — intervention group
Group type: EXPERIMENTAL
Intervention: Form 1 (brief information about common risks and risk factors associated with IVCM)
Number of subjects: 265
Study 16372689 — intervention group
Group type: COMPARATOR
Intervention: Form 2 (comprehensive information about risks and risk factors associated with IVCM)
Number of subjects: 265
Study 11735758 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA treatment
Number of subjects: 616
Study 11735758 — intervention group
Group type: COMPARATOR
Intervention: placebo treatment
Number of subjects: 616
Study 9013219 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation and guided imagery intervention (RG)
Number of subjects: 50
Study 9013219 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 50
Study 8736043 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine
Number of subjects: 0
Study 8736043 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol (CORT) levels
Number of subjects: 0
Study 8736043 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol (CORT) influence
Number of subjects: 0
Study 3430589 — intervention group
Group type: EXPERIMENTAL
Intervention: Team competitions
Number of subjects: 0
Study 3430589 — intervention group
Group type: COMPARATOR
Intervention: Individual competition
Number of subjects: 0
Study 31447131 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin/Laropiprant (2000/40 mg/d)
Number of subjects: 25673
Study 28891419 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to Holy Qur'an recitation in combination with endurance‐resistance training (n = 28)
Number of subjects: 53
Study 28891419 — intervention group
Group type: COMPARATOR
Intervention: Endurance‐resistance training only (n = 25)
Number of subjects: 53
Study 26568566 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent ART (I-ART) for 2 years, consisting of 6 month periods on once-daily boosted-PI-based ART, alternating with 6 month periods without ART.
Number of subjects: 44
Study 26568566 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent ART (I-ART) for 2 years.
Number of subjects: 44
Study 24989409 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT RNA cluster analysis (normal average approach)
Number of subjects: 49
Study 24989409 — intervention group
Group type: COMPARATOR
Intervention: SPECT RNA phase analysis
Number of subjects: 49
Study 24989409 — intervention group
Group type: COMPARATOR
Intervention: PET scar size analysis
Number of subjects: 49
Study 22115984 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony stimulating factor (G‐CSF)
Number of subjects: 18
Study 22115984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 19237716 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with folic acid (2.5 mg/d), pyridoxine hydrochloride (50 mg/d), and cyanocobalamin (1 mg/d)
Number of subjects: 5205
Study 19237716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5205
Study 18070474 — intervention group
Group type: EXPERIMENTAL
Intervention: Voltage-gated potassium channel current density in ACS patients
Number of subjects: 12
Study 18070474 — intervention group
Group type: EXPERIMENTAL
Intervention: Kv1.3 protein expression in ACS patients
Number of subjects: 12
Study 15765890 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 10305
Study 15765890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10305
Study 11560871 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (200 mg)
Number of subjects: 13
Study 11560871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 9934573 — intervention group
Group type: EXPERIMENTAL
Intervention: Local injection of lidocaine hydrochloride
Number of subjects: 15
Study 9934573 — intervention group
Group type: COMPARATOR
Intervention: Local injection of saline
Number of subjects: 15
Study 9934573 — intervention group
Group type: COMPARATOR
Intervention: Dry needling
Number of subjects: 15
Study 7946688 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol 350 mg I/ml with NaCl 28 mmol/l
Number of subjects: 117
Study 7946688 — intervention group
Group type: COMPARATOR
Intervention: iohexol only
Number of subjects: 117
Study 3652930 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 12 micrograms/kg i.v.
Number of subjects: 5
Study 3652930 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee (4 cups of Italian style 'espresso' coffee)
Number of subjects: 5
Study 3652930 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee plus naloxone simultaneously
Number of subjects: 5
Study 29078743 — intervention group
Group type: EXPERIMENTAL
Intervention: Scores + Visual + Force feedback
Number of subjects: 14
Study 29078743 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual + Force feedback
Number of subjects: 14
Study 27031165 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective microorganism-X (EM-X) supplementation (70 ml·day(‐1))
Number of subjects: 6
Study 27031165 — intervention group
Group type: COMPARATOR
Intervention: Placebo (TEMPPLA or HOTPLA)
Number of subjects: 6
Study 24873159 — intervention group
Group type: EXPERIMENTAL
Intervention: Shang Ring circumcision by transverse incision in the distal penis foreskin and pull-up of the interior board
Number of subjects: 130
Study 24873159 — intervention group
Group type: COMPARATOR
Intervention: Conventional transverse incision and longitudinal suture of the frenulum praeputii
Number of subjects: 130
Study 23751149 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm-control strategy
Number of subjects: 304
Study 23751149 — intervention group
Group type: COMPARATOR
Intervention: Rate-control strategy
Number of subjects: 304
Study 20078917 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg, 3 times daily as needed for up to 7 days
Number of subjects: 61
Study 20078917 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine 5 mg, 3 times daily as needed for up to 7 days
Number of subjects: 61
Study 20078917 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ibuprofen and cyclobenzaprine, 3 times daily as needed for up to 7 days
Number of subjects: 61
Study 20078917 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 61
Study 18616688 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone (50 to 150 mg at bedtime) for 12 weeks
Number of subjects: 173
Study 18616688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 16911750 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily treatment (10 treatments, on business days)
Number of subjects: 16
Study 16911750 — intervention group
Group type: COMPARATOR
Intervention: Spaced treatment (five treatments, on spaced business days)
Number of subjects: 16
Study 11868063 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard polarity (anterior pad = cathode) shocks
Number of subjects: 110
Study 11868063 — intervention group
Group type: COMPARATOR
Intervention: Reversed polarity (anterior pad = anode) shocks
Number of subjects: 110
Study 9892586 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/d
Number of subjects: 4159
Study 9892586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4159
Study 8620173 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticosteroids (treated for 5-7 years)
Number of subjects: 46
Study 8620173 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 healthy persons)
Number of subjects: 46
Study 2126741 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic NTG oral spray (0.8 mg)
Number of subjects: 20
Study 2126741 — intervention group
Group type: COMPARATOR
Intervention: Lipophilic NTG oral spray (0.8 mg)
Number of subjects: 20
Study 6989433 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training (12-minute walk and stair climbing exercises, supervised once a week)
Number of subjects: 33
Study 6989433 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 33
Study 6989433 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Number of subjects: 33
Study 6989433 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training and Control group
Number of subjects: 33
Study 31704264 — intervention group
Group type: EXPERIMENTAL
Intervention: Single UM171-expanded cord blood transplantation
Number of subjects: 22
Study 31826005 — intervention group
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Number of subjects: 416
Study 31826005 — intervention group
Group type: COMPARATOR
Intervention: E/C/F/TDF
Number of subjects: 416
Study 28060837 — intervention group
Group type: EXPERIMENTAL
Intervention: CSL‐111 (reconstituted HDL) 40 mg/kg, administered as 4 weekly intravenous infusions
Number of subjects: 33
Study 28060837 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 33
Study 28060837 — intervention group
Group type: EXPERIMENTAL
Intervention: CSL‐111 (reconstituted HDL)
Number of subjects: 33
Study 25640884 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigator assistance for cancer screening (experimental condition, n = 242)
Number of subjects: 488
Study 25640884 — intervention group
Group type: COMPARATOR
Intervention: Cancer education (control condition, n = 246)
Number of subjects: 488
Study 24096219 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.375% ropivacaine + 25μg of fentanyl
Number of subjects: 40
Study 24096219 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine + 25μg of fentanyl
Number of subjects: 40
Study 21336617 — intervention group
Group type: COMPARATOR
Intervention: Dronedarone 400 mg bid
Number of subjects: 0
Study 21336617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19586828 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/mL morphine and 10 microg/mL nalbuphine (1:100)
Number of subjects: 174
Study 19586828 — intervention group
Group type: COMPARATOR
Intervention: 1 mg/mL morphine
Number of subjects: 174
Study 17524152 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart surgery (coronary artery bypass surgery)
Number of subjects: 0
Study 15129827 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (09:00 h after sleep)
Number of subjects: 29
Study 15129827 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (12 h later)
Number of subjects: 29
Study 15129827 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 29
Study 11210399 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbatrol (200 mg) with a high-fat meal
Number of subjects: 12
Study 11210399 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbatrol (200 mg) fasted
Number of subjects: 12
Study 11210399 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbatrol (200 mg) sprinkled over applesauce (but otherwise fasted)
Number of subjects: 12
Study 9558184 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal education + NSAID information sheet
Number of subjects: 56
Study 9558184 — intervention group
Group type: COMPARATOR
Intervention: Verbal education only
Number of subjects: 56
Study 7542052 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (200 mg/day for 4 weeks or individualized dosing for 6 weeks)
Number of subjects: 14
Study 7542052 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3-4 weeks)
Number of subjects: 14
Study 2377588 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast self-examination training plus maintenance
Number of subjects: 637
Study 2377588 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast self-examination training alone
Number of subjects: 637
Study 2377588 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast self-examination maintenance
Number of subjects: 637
Study 2377588 — intervention group
Group type: COMPARATOR
Intervention: Control (full measurement)
Number of subjects: 637
Study 2377588 — intervention group
Group type: COMPARATOR
Intervention: Low-measurement control
Number of subjects: 637
Study 356970 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy (DTIC 250 mg/m2 iv, Days 1-5; actinomycin D 0.5 mg/day iv, Days 1-5; methanol extracted residue of bacillus Calmette-Guérin 0.5 mg intradermally every 5 weeks)
Number of subjects: 28
Study 356970 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (DTIC 250 mg/m2 iv, Days 1-5; actinomycin D 0.5 mg/day iv, Days 1-5)
Number of subjects: 28
Study 30010195 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced breathing at 0.1 Hz (with cover story)
Number of subjects: 83
Study 30010195 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced breathing at 0.1 Hz (without cover story)
Number of subjects: 83
Study 30010195 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced breathing at 0.1 Hz (both groups)
Number of subjects: 83
Study 30010195 — intervention group
Group type: COMPARATOR
Intervention: Paced breathing at 0.28 Hz (control)
Number of subjects: 83
Study 26070922 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured telephone call
Number of subjects: 84
Study 26070922 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured text message
Number of subjects: 84
Study 26070922 — intervention group
Group type: COMPARATOR
Intervention: Control group (no post-procedure communication)
Number of subjects: 84
Study 24793004 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention program
Number of subjects: 26
Study 24793004 — intervention group
Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 26
Study 22652211 — intervention group
Group type: EXPERIMENTAL
Intervention: GIC (glass ionomer cement)
Number of subjects: 45
Study 22652211 — intervention group
Group type: EXPERIMENTAL
Intervention: GSGIC (10% grape seed extract and GIC)
Number of subjects: 45
Study 22652211 — intervention group
Group type: EXPERIMENTAL
Intervention: CPPGIC (10% casein phosphopeptide-amorphous calcium phosphate and GIC)
Number of subjects: 45
Study 22652211 — intervention group
Group type: COMPARATOR
Intervention: Control (lingual half of teeth)
Number of subjects: 45
Study 20445533 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril
Number of subjects: 0
Study 20445533 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 0
Study 20445533 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of benazepril and valsartan
Number of subjects: 0
Study 20445533 — intervention group
Group type: COMPARATOR
Intervention: Control (single-agent treatment with benazepril or valsartan)
Number of subjects: 0
Study 18349171 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers (specific mention of metoprolol and other beta-blockers)
Number of subjects: 2176
Study 18349171 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 2176
Study 16045848 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid injections
Number of subjects: 82
Study 16045848 — intervention group
Group type: COMPARATOR
Intervention: Footwear modification with orthoses
Number of subjects: 82
Study 12942393 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B
Number of subjects: 1591
Study 12942393 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 1591
Study 12942393 — intervention group
Group type: EXPERIMENTAL
Intervention: Candida parapsilosis fungemia
Number of subjects: 1591
Study 12942393 — intervention group
Group type: COMPARATOR
Intervention: Observational cohort
Number of subjects: 1591
Study 10574592 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall haemostatic potential in plasma (OHPP) measured by ABS-sum
Number of subjects: 30
Study 8706442 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (varying dosages)
Number of subjects: 58
Study 8706442 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol in combination with laminaria or tamoxifen
Number of subjects: 58
Study 8706442 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 58
Study 8993489 — intervention group
Group type: EXPERIMENTAL
Intervention: tacrine
Number of subjects: 73
Study 8993489 — intervention group
Group type: COMPARATOR
Intervention: PLACEBO
Number of subjects: 73
Study 6193962 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body hyperthermia
Number of subjects: 27
Study 3865687 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 (100-500 micrograms ml-1)
Number of subjects: 15
Study 3865687 — intervention group
Group type: EXPERIMENTAL
Intervention: PGF2 alpha (0.1-100 micrograms ml-1)
Number of subjects: 15
Study 3865687 — intervention group
Group type: COMPARATOR
Intervention: Acetylcholine (0.1-50 mg ml-1)
Number of subjects: 15
Study 3865687 — intervention group
Group type: COMPARATOR
Intervention: Citric acid (5-20% w/v)
Number of subjects: 15
Study 3865687 — intervention group
Group type: EXPERIMENTAL
Intervention: PGF2 alpha and PGE2
Number of subjects: 15
Study 31492716 — intervention group
Group type: EXPERIMENTAL
Intervention: IV glucose infusion (10% glucose at 410 mL/h)
Number of subjects: 3
Study 31492716 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose supplementation (2% concentration soft drink)
Number of subjects: 3
Study 31492716 — intervention group
Group type: COMPARATOR
Intervention: Placebo (soft drink with aspartame, acesulfame-K)
Number of subjects: 3
Study 31492716 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy men)
Number of subjects: 3
Study 29863462 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild-gain amplification for 4 weeks
Number of subjects: 39
Study 29863462 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 39
Study 26768929 — intervention group
Group type: EXPERIMENTAL
Intervention: 3mg/kg 0.5% prilocaine + 2 mL (100mg) tramadol
Number of subjects: 51
Study 26768929 — intervention group
Group type: EXPERIMENTAL
Intervention: 3mg/kg 0.5% prilocaine + 2 mL (8 mg) lornoxicam
Number of subjects: 51
Study 26768929 — intervention group
Group type: COMPARATOR
Intervention: 3mg/kg 0.5% prilocaine
Number of subjects: 51
Study 24657033 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcystein 150 mg/kg followed by 50 mg/kg for 6 hours in 0.9% saline
Number of subjects: 70
Study 24657033 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcystein
Number of subjects: 70
Study 24657033 — intervention group
Group type: COMPARATOR
Intervention: Control (0.9% saline)
Number of subjects: 70
Study 22782476 — intervention group
Group type: EXPERIMENTAL
Intervention: Advocate® (imidacloprid 10%/moxidectin 1%)
Number of subjects: 36
Study 22782476 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 36
Study 20490567 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrapro mesh
Number of subjects: 402
Study 20490567 — intervention group
Group type: COMPARATOR
Intervention: Prolene mesh
Number of subjects: 402
Study 18064525 — intervention group
Group type: EXPERIMENTAL
Intervention: Room air
Number of subjects: 14
Study 18064525 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 l/min oxygen via nasal prongs
Number of subjects: 14
Study 18064525 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 l/min oxygen through a rebreathing face mask
Number of subjects: 14
Study 18064525 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen as needed to achieve an arterial oxygen pressure (arterial pO(2)) of 200 mmHg
Number of subjects: 14
Study 18064525 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen as needed to achieve an arterial oxygen pressure (arterial pO(2)) of 300 mmHg
Number of subjects: 14
Study 15921933 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 9
Study 15921933 — intervention group
Group type: COMPARATOR
Intervention: Glycopyrrolate (Control)
Number of subjects: 9
Study 14519089 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral GP IIb/IIIa inhibitors
Number of subjects: 0
Study 14519089 — intervention group
Group type: COMPARATOR
Intervention: Intravenous GP IIb/IIIa receptor blockers
Number of subjects: 0
Study 12862143 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg ibuprofen
Number of subjects: 113
Study 12862143 — intervention group
Group type: COMPARATOR
Intervention: 1000 mg paracetamol
Number of subjects: 113
Study 8873736 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin
Number of subjects: 212
Study 8873736 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin
Number of subjects: 212
Study 8873736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 1891788 — intervention group
Group type: EXPERIMENTAL
Intervention: WBC-reduced platelet concentrates (PCs) and red cells (RBCs) with fewer than 10(6) WBCs per unit
Number of subjects: 31
Study 1891788 — intervention group
Group type: COMPARATOR
Intervention: Standard blood components with a mean of 0.1 x 10(9) WBCs (PCs) and 1 x 10(9) WBCs (RBCs) per unit
Number of subjects: 31
Study 6743481 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 600 mg twice daily
Number of subjects: 0
Study 6743481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31439299 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation including pulmonary vein isolation (PVI)
Number of subjects: 610
Study 31439299 — intervention group
Group type: COMPARATOR
Intervention: Ablation excluding pulmonary vein isolation (non-PVI)
Number of subjects: 610
Study 31439299 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation including PVI
Number of subjects: 610
Study 28881355 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Loss Intervention (WLI)
Number of subjects: 40
Study 28881355 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 27646850 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 157
Study 27646850 — intervention group
Group type: COMPARATOR
Intervention: Control (no fibrin glue)
Number of subjects: 157
Study 24717711 — intervention group
Group type: EXPERIMENTAL
Intervention: APF-30
Number of subjects: 25
Study 24717711 — intervention group
Group type: EXPERIMENTAL
Intervention: APF-15
Number of subjects: 25
Study 24717711 — intervention group
Group type: EXPERIMENTAL
Intervention: APF-0
Number of subjects: 25
Study 24717711 — intervention group
Group type: EXPERIMENTAL
Intervention: APF-cotton
Number of subjects: 25